Transforming Oncology

Advancing GBM treatment through pioneering research and transformative therapies for improved patient outcomes.

Publications & Presentations

Our Focus

Our primary focus is on glioma, specifically glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.

Learn More

For Patients

CNS Pharmaceuticals is dedicated to supporting patients and their families throughout their cancer journey. Our 'For Patients' page offers valuable resources, including information about our clinical trials, treatment options, and support networks. Visit our 'For Patients' page to learn more and find the help you need.

Learn More

Our Pipeline

Our primary focus is on glioblastoma multiforme, an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.

Learn More

Latest News

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Read More

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Read More

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Read More
See All News Releases

Investor Relations

Explore our financial data and market performance. Get a clear picture of our strategic outlook.

Learn More

Presentations

Access our comprehensive publications and presentations page for information on our research programs.

Learn More

Email Alerts

Get timely updates on our latest developments. Subscribe to email alerts for new press releases, events, and filings.

Learn More

Pipeline

Track our ongoing research and development projects. Monitor the progress and future of our drug programs.

Learn More